the toxicity of doxorubicin , as determined by growth inhibition and clonogenic assays , was significantly potentiated in the bso-treated gsh-depleted cells relative to control breast tumor cells , and a dose-modifying factor of 5 to 7 was observed .
C0013089
doxorubicin
C1458155
breast